-
Featured Authors
-
Archives
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Latest From Biotech Now
IPAB: Bad Medicine for Patient Care
The Independent Payment Advisory Board is bad medicine for patient care, deficit reduction and containing Medicare costs. This board, consisting of 15 bureaucrats appointed by the President, has been given the power to make decisions affecting patients’ quality of care, with almost no oversight and no means for challenging its decisions. IPAB must be repealed. There is widespread support among patient advocacy groups and members of Congress on both sides of the aisle for full Read More >
Triumph of the anti-GMO movement would be a disaster
In Discover magazine’s Collide-a-Scape blog, Keith Kloor writes about Why GMOs Matter. Kloor reflects on the debate around GMOs and the various positions articulated by others such as University of Wyoming’s Andrew Kniss, Berkley’s Michael Eisen and Author Ramez Naam. Kniss believes that the GMO debate is overlooking an essential voice: “While activist groups, scientists, and journalists yell past each other in this debate, the people who are actually using and benefiting from the technology are largely ignored. So too are Read More >
More than a Quarter of 2013 US-Based Biotech IPOs Call California Home
And of those 39 US-based biotech companies, five of them are from San Diego, highlighting the region’s growing importance as hub for the biotech and life science industries. According to a recently authored BIO article in the Union Tribune San Diego, there are several reasons at play for the strong public offerings – enactment of the JOBS Act, an eager investor market and increasing regulatory transparency resulting from PDUFA V. As powerful as the JOBS Read More >
NPR’s Shots Blog: Vaccine Fears Fueled The Resurgence Of Preventable Diseases
This past weekend, Michaeleen Doucleff at NPR’s Shots blog shared a fascinating but disturbing map from the Council on Foreign Relations, How Vaccine Fears Fueled The Resurgence Of Preventable Diseases. The map covers 2008-2013 and shows outbreaks of measles, mumps, rubella, polio, whooping cough, and other diseases that are preventable with vaccines. As the article notes, we’ve seen a large increase in whooping cough cases here in the US. While the 24,000 cases seen in Read More >
Stable Policy Can Help Assure Unwavering Investment in U.S. Biofuels
The Renewable Fuel Standard (RFS) is a unique federal policy that has, just as its bipartisan supporters intended, spurred major domestic and international investment in US biofuels production and it is essential to maintaining a growing market for second generation biofuels. That growing market helps attract investment to advanced biofuel companies who are trying to expand their infrastructure, scale up their production line, and improve their technology foundation. Unfortunately, the Environmental Protection Agency’s (EPA) recent Read More >
